Sumatriptan contraindications and the serotonin syndrome

Annals of Pharmacotherapy

Volumn 32, Issue 1, 1998, Pages 33-38

  Gardner, David M ^a,b   Lynd, Larry D ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Brit Columbia Reg Adverse Drug R   (Canada)

^d British Columbia Drug and Poison Information Centre   (Canada)

Author keywords

Serotonin syndrome; Sumatriptan

Indexed keywords

BUSPIRONE; FLUOXETINE; FLUVOXAMINE; LITHIUM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG CONTRAINDICATION; DRUG MONITORING; DRUG SAFETY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MIGRAINE; NEUROMUSCULAR DISEASE; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTONIN SYNDROME; SUBCUTANEOUS DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 0031910976     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17204     Document Type: Article

References (28)

1. Gordon ML, Brown SL, Lipton RB, Korn ML, Kay SR, Solomon S, et al. Serotonergic parallels in migraine, depression and anxiety. In: Nappi G, Bono G, Sandrini G, Martignoni E, Micieli G, eds. Headache and depression. New York: Raven Press, 1991:21-41.
2. Noack H, Rothrock JF. Migraine: definitions, mechanisms, and treatment. South Med J 1996;89:762-9.
3. Montgomery SA. Selective serotonin reuptake inhibitors in the acute treatment of depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1043-52.
4. Kahn RE, Van Praag HM, Wetzler S, Asnis GM, Barr G. Serotonin and anxiety revisited. Biol Psychiatry 1988;23:189-208.
5. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
6. Breslau N, Davis GC, Schultz LR, Peterson EL. Migraine and major depression: a longitudinal study. Headache 1994;34:387-93.
7. Stewart WF, Linet MS, Celentano DD. Migraine headaches and panic attacks. Psychosom Med 1989;51:559-69.
8. Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry 1990;47:849-53.
9. Marazziti D, Toni C, Pedri S, Bonuccelli U, Pavese N, Nuti A, et al. Headache, panic disorder and depression: comorbidity or a spectrum? Neuropsychobiology 1995;31:125-9.
10. Product monograph. Imitrex (sumatriptan). Mississauga, Ontario: Glaxo Wellcome Inc., December 1996.
11. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995;13:94-104.
12. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527-33.
13. Mills MC. Serotonin syndrome. Am Fam Phys 1995;52:1475-82.
14. Martin TG. Serotonin syndrome. Ann Emerg Med 1996;28:520-6.
15. Silberstein SD. Serotonin (5-HT) and migraine. Headache 1994;34:408-17.
16. Beattie DT, Connor HE, Feniuk W, Humphrey PPA. The pharmacology of sumatriptan. Rev Contemp Pharmacother 1994;5:285-94.
17. Baldessarini RJ. Lithium salts and antimanic agents. In: Baldessarini RJ. Chemotherapy in psychiatry: principles and practice. Cambridge, MA: Harvard University Press, 1985:93-129.
18. Leung M, Ong M. Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache 1995;35:488-9.
19. Shulman RW. The serotonin syndrome: a tabular guide. Can J Clin Pharmacol 1995;2:139-44.
20. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996;16:323-7.
21. Blakeborough P, Fowler PA, Ashford EA. The use of sumatriptan in patients taking prophylatic agents (abstract). Presented at the VIth International Headache Congress, Paris, August 1993.
22. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol 1995;15:106-9.
23. Wing YK, Clifford EM, Sheehan BD, Campling GM, Hockney RA, Cowen PJ. Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmacology 1996;124:377-9.
24. Szabo CP. Fluoxetine and sumatriptan: possibly a counterproductive combination. J Clin Psychiatry 1995;56:37-8.
25. Diamond S. The use of sumatriptan in patients on monoamine oxidase inhibitors. Neurology 1995;45:1039-40.
26. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme system responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994;47:1253-7.
27. 1D autoreceptors on the modulation of 5-HT release in guinea-pig mesencephalic raphe, hippocampus and frontal cortex. Br J Pharmacol 1996;118:681-9.
28. Pineyro G, Blier P. Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine(1D) receptors - effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration. J Pharmacol Exp Ther 1996;276:697-707.